doi: 10.14202/IJOH.2016.69-74
Share this article on [Facebook] [LinkedIn]
Article history: Received: 20-08-2016, Accepted: 01-11-2016, Published online: 22-11-2016
Corresponding author: Mashkoor Mohsin
E-mail: mashkoormohsin@uaf.edu.pk
Citation: Bukhari AA, Arshad MI, Raza S, Azam M, Sajjad-ur-Rahman, Mohsin M. Emergence of extended spectrum beta-lactamases-producing strains belonging to cefotaxime-M-1 class from intensive care units patients and environmental surfaces in Pakistan. Int J One Health 2016;2:69-74.Aim: The emergence of multidrug-resistant (MDR) bacteria is the most dangerous threat for the treatment of infectious diseases. The aim of this study was to detect and characterize extended spectrum beta-lactamases (ESBLs) and carbapenemase-producing Klebsiella pneumoniae and Escherichia coli among patients and environment of intensive care units (ICUs) of three tertiary care hospitals in Pakistan.
Materials and Methods: A total of 82 samples from ICU's patients and inanimate environment (injection trays, wash basins, door handles, hand swabs of professionals, and ICU fridges) were screened for ESBL by culturing on CHROMagar-ESBL. ESBL and carbapenemases production were confirmed by double disc synergy test and modified Hodge's test, respectively. Polymerase chain reaction was used to detect ESBL encoding genes bla cefotaxime (CTX-M), blaCTX-M-1, blaCTX-M-2, blaCTX-M-9, blaTEM, blaSHV and carbapenemase genes blaKPC, bla New Delhi metallo-beta-lactamase-1, blaOXA-48 and blaVIM.
Results: Overall, ESBL production was found high 30/82 (36.5%) among isolates of which 15.8% K. pneumoniae and 20.7% E. coli were identified. All the K. pneumoniae and majority of E. coli isolates were MDR, i.e., resistance to three or more antimicrobial categories. Molecular characterization showed the blaCTX-M-1 as the predominant genotype found in 17/21 (80%) of the isolates. None of the strains was found positive for carbapenemase-encoding genes.
Conclusion: In conclusion, this study demonstrates the emergence of MDR ESBL producing strains among ICU patients and hospital environment, posing a serious threat for the control of nosocomial infections.
Keywords: antimicrobial resistance, Escherichia coli, extended spectrum beta lactamase, Klebsiella pneumoniae, nosocomial infections.
1. Odonkor ST, Addo KK. Bacteria resistance to antibiotics: Recent trends and challenges. Int J Biol Med Res 2011;2:1204-10.
2. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013;13:1057-98. [Crossref]
3. Flores-Gonzalez JC, Hernandez-Gonzalez A, Rodriguez-Lopez C, Roldan-Cano V, Rubio-Qui-ones F, Quintero-Otero S, et al. Nosocomial urinary tract infection in critical pediatric patients. Med Intensiva 2011;35:344-8. [Crossref] [PubMed]
4. Chong Y, Ito Y, Kamimura T. Genetic evolution and clinical impact in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol 2011;11:1499-504. [Crossref] [PubMed]
5. Wu G, Day MJ, Mafura MT, Nunez-Garcia J, Fenner JJ, Sharma M, et al. Comparative analysis of ESBL-positive Escherichia coli isolates from animals and humans from the UK, The Netherlands and Germany. PLoS One 2013;8:e75392. [Crossref] [PubMed] [PMC]
6. Gupta A, Ampofo K, Rubenstein D, Saiman L. Extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections: A review of the literature. J Perinatol 2002;23:439-43. [Crossref] [PubMed]
7. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005;18:657-86. [Crossref] [PubMed] [PMC]
8. Rawat D, Nair D. Extended-spectrum β-lactamases in gram negative bacteria. J Glob Infect Dis 2010;2:263-74. [Crossref] [PubMed] [PMC]
9. Ruppe E. Epidemiology of extended-spectrum-beta lactamses: Rise of the CTX-M. Antibiotiques 2010;12:3-16. [Crossref]
10. Amos GC, Hawkey PM, Gaze WH, Wellington EM. Waste water effluent contributes to the dissemination of CTX-M-15 in the natural environment. J Antimicrob Chemother 2014;69:1785-91. [Crossref] [PubMed] [PMC]
11. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 2008;8:159-66. [Crossref]
12. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. Extended-spectrum β-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: A global perspective. Clin Microbiol Infect 2012;18:646-55. [Crossref] [PubMed]
13. Cui L, Zhao J, Lu J. Molecular characteristics of extended spectrum β-lactamase and carbapenemase genes carried by carbapenem-resistant Enterobacter cloacae in a Chinese university hospital. Turk J Med Sci 2015;45:1321-8. [Crossref] [PubMed]
14. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602. [Crossref]
15. Poirel L, Pitout JD, Nordmann P. Carbapenemases: Molecular diversity and clinical consequences. Future Microbiol 2007;2:501-12. [Crossref] [PubMed]
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement M100-S20. Wayne, PA. Clinical and Laboratory Standards Institute; 2010.
17. Sultan BA, Khan E, Hussain F, Nasir A, Irfan S. Effectiveness of modified Hodge test to detect NDM-1 carbapenemases?: An experience from Pakistan. J Pak Med Assoc 2013;63:955-60.
18. Sambrook J, Fritsche E, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1989.
19. Cullik A, Pfeifer Y, Prager R, von Baum H, Witte W. A novel IS26 structure surrounds blaCTX-M genes in different plasmids from German clinical Escherichia coli isolates. J Med Microbiol 2010;59:580-7. [Crossref] [PubMed]
20. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum? β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. Health care system. Antimicrob Agents Chemother 2007;51:4015-21. [Crossref] [PubMed] [PMC]
21. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, et al. Effects of phenotype and genotype on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clinic Microbiol 2007;45:199-205. [Crossref] [PubMed] [PMC]
22. Xu L, Ensor V, Gossain S, Nye K, Hawkey P. Rapid and simple detection of blaCTX-M genes by multiplex PCR assay. J Med Microbiol 2005;54:1183-7. [Crossref] [PubMed]
23. Pfeifer Y, Witte W, Holfelder M, Busch J, Nordmann P, Poirel L. NDM-1-producing Escherichia coli in Germany. Antimicrob Agents Chemother 2011;55:1318-9. [Crossref] [PubMed] [PMC]
24. Grobner S, Linke D, Schutz W, Fladerer C, Madlung J, Autenrieth IB, et al. Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tubingen, Germany. J Med Microbiol 2009;58:912-22. [Crossref] [PubMed]
25. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009;73:345-54. [Crossref] [PubMed]
26. Habeeb MA, Haque A, Nematzadeh S, Iversen A, Giske CG. High prevalence of 16S rRNA methylase RmtB among CTX-M extended-spectrum β-lactamase-producing Klebsiella pneumoniae from Islamabad, Pakistan. Int J Antimicrob Agents 2013;41:524-6. [Crossref] [PubMed]
27. Mushtaq S, Irfan S, Sarma JB, Doumith M, Pike R, Pitout J, et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 2011;66:2002-5. [Crossref] [PubMed]
28. Ahmed I, Sajed M, Sultan A, Murtaza I, Yousaf S, Maqsood B. The erratic antibiotic susceptibility patterns of bacterial pathogens causing urinary tract infections. EXCLI J 2015;14:916-25. [PubMed] [PMC]
29. Jabeen K, Zafar A, Hasan R. Frequency and sensitivity pattern of extended spectrum beta lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J Pak Med Assoc 2005;55:436-9. [PubMed]
30. Khan E, Schneiders T, Zafar A, Aziz E, Parekh A, Hasan R. Emergence of CTX-M Group 1-ESBL producing Klebsiella pneumonia from a tertiary care centre in Karachi, Pakistan. J Infect Dev Ctries 2010;4:472-6. [Crossref] [PubMed]
31. Habeeb MA, Haque A, Iversen A, Giske CG. Occurrence of virulence genes, 16S rRNA methylases, and plasmid-mediated quinolone resistance genes in CTX-M-producing Escherichia coli from Pakistan. Eur J Clin Microbiol Infect Dis 2014;33:399-409. [Crossref] [PubMed]
32. Tangden T, Adler M, Cars O, Sandegren L, Lowdin E. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob Chemother 2013;68:1319-26. [Crossref] [PubMed]
33. Carvalhaes CG, Picao RC, Nicoletti AG, Xavier DE, Gales AC. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: Be aware of false positive results. J Antimicrob Chemother 2010;65:249-51. [Crossref] [PubMed]